Publication

Targeting senescence to delay progression of multiple sclerosis

Oost, W., Talma, N., Meilof, J. F. & Laman, J. D., Nov-2018, In : Journal of Molecular Medicine. 96, 11, p. 1153-1166 14 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Multiple sclerosis (MS) is a chronic and often progressive, demyelinating disease of the central nervous system (CNS) white and gray matter and the single most common cause of disability in young adults. Age is one of the factors most strongly influencing the course of progression in MS. One of the hallmarks of aging is cellular senescence. The elimination of senescent cells with senolytics has very recently been shown to delay age-related dysfunction in animal models for other neurological diseases. In this review, the possible link between cellular senescence and the progression of MS is discussed, and the potential use of senolytics as a treatment for progressive MS is explored. Currently, there is no cure for MS and there are limited treatment options to slow the progression of MS. Current treatment is based on immunomodulatory approaches. Various cell types present in the CNS can become senescent and thus potentially contribute to MS disease progression. We propose that, after cellular senescence has indeed been shown to be directly implicated in disease progression, administration of senolytics should be tested as a potential therapeutic approach for the treatment of progressive MS.

Original languageEnglish
Pages (from-to)1153-1166
Number of pages14
JournalJournal of Molecular Medicine
Volume96
Issue number11
Early online date18-Sep-2018
Publication statusPublished - Nov-2018

    Keywords

  • Aging, Senolytics, Glia, Neurodegeneration, Inflammation, Autoimmunity, CENTRAL-NERVOUS-SYSTEM, VASCULAR ENDOTHELIAL-CELLS, CD4(+)CD28(-) T-CELLS, BLOOD-BRAIN-BARRIER, CELLULAR SENESCENCE, SECRETORY PHENOTYPE, CNS REMYELINATION, SENOLYTIC DRUGS, PRECURSOR CELLS, CANCER CELLS

Download statistics

No data available

ID: 65262611